Drug-resistant urothelial canc cell lines display diverse sensitivity profiles to potential second-line therapeutics

Translational Oncology

Volumn 8, Issue 3, 2015, Pages 210-216

  Vallo, Stefan ^a   Michaelis, Martin ^b   Rothweiler, Florian ^a   Bartsch, Georg ^a   Gust, Kilian M ^a   Limbart, Dominik M ^a   Rödel, Franz ^a   Wezel, Felix ^c   Haferkamp, Axel ^a   Cinatl, Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF KENT   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; LAROTAXEL; METHOTREXATE; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PACLITAXEL; PEMETREXED; TOPOTECAN; VINBLASTINE; VINFLUNINE;

ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE ONTOLOGY; GROWTH CURVE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MTT ASSAY; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 84930714894     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.04.002     Document Type: Article

References (42)

1. [1] von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, and Arning M (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23, 4602–4608.
2. 2] Pectasides D, Pectasides M, and Economopoulos T (2006). Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Cancer Treat Rev 32, 456–470.
3. Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, O'Leary JJ, Gottesman M, and Clynes M (2012). Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 7, e40717.
4. Breier A, Gibalova L, Seres M, Barancik M, and Sulova Z (2013). New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 13, 159–170.
5. [5] Petrylak DP, Scher HI, Reuter V, O'Brien JP, and Cordon-Cardo C (1994). P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5, 835–840.
6. Kakehi Y, Wu WJ, Kim WJ, Arao S, Fukumoto M, and Yoshida O (1995). Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers. Int J Urol 2, 309–315.
7. [7] Chen Z, Zhang Y, Zhang X, Du G, Yang W, Hu Z, Li J, and Zhang Y (2001). Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication. J Tongji Med Univ 21, 56–58.
8. [8] Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Hsieh CY, and Pu YS (2000). Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 20, 3221–3225.
9. [9] Serretta V, Pavone C, Allegro R, Vella M, Sanguedolce R, Porcasi R, Morello V, Tomasino RM, and Pavone-Macaluso M (2003). Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma. J Cancer Res Clin Oncol 129, 472–476.
10. [10] Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, and Schuler M, et al (2010). MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12, 628–636.
11. [11] Rioja J, Bandrés E, Rosell Costa D, Rincón A, López I, Zudaire Bergera JJ, García Foncillas J, Gil MJ, Panizo A, and Plaza L, et al (2010). Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma. BJU Int 107, 1833–1838.
12. Aparicio S and Caldas C (2013). The implications of clonal genome evolution for cancer medicine. N Engl J Med 368, 842–851.
13. [13] Crockford A, Jamal-Hanjani M, Hicks J, and Swanton C (2014). Implications of intratumour heterogeneity for treatment stratification. J Pathol 232, 264–273.
14. [14] Pantel K and Alix-Panabières C (2013). Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 73, 6384–6388.
15. [15] Sharma SV, Haber DA, and Settleman J (2010). Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10, 241–253.
16. [16] Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, and de la Iglesia-Vicente J, et al (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22, 373–388.
17. [17] Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, and Al-Abed Y, et al (2010). Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 12, 1023–1030.
18. [18] Weber K, Thomaschewski M, Benten D, and Fehse B (2012). RGB marking with lentiviral vectors for multicolor clonal cell tracking. Nat Protoc 5, 839–849.
19. [19] Rutigliano L, Corradetti B, Valentini L, Bizzaro D, Meucci A, Cremonesi F, and Lange-Consiglio A (2013). Molecular characterization and in vitro differentiation of feline progenitor-like amniotic epithelial cells. Stem Cell Res Ther 30, 133.
20. [20] Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, and Rödel F, et al (2011). Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2, e243.
21. [21] Rohde D, Brehmer B, Kapp T, Valdor M, and Jakse G (1998). Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV). Urol Res 26, 249–257.
22. [22] Rigby CC and Franks LM (1970). A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 24, 746–754.
23. Lee YG, Macoska JA, Korenchuk S, and Pienta KJ (2002). MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 4, 291–294.
24. Etievant C, Barret JM, Kruczynski A, Perrin D, and Hill BT (1998). Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 16, 3–17.
25. van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, and Vellenga E (2000). P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6, 3205–3214.
26. Gerullis H (2011). Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy. Drugs Today (Barc) 47, 17–25.
27. [27] Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, and Constantinidis C, et al (2013). Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol 24, 1011–1017.
28. [28] Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, and Su YZ (1993). Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer 53, 478–485.
29. [29] Yang X and Pagé M (1995). P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res 7, 619–624.
30. [30] Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ, and Choi CH (2005). Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 11, 618–622.
31. [31] Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, and Hamilton TC (1993). Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53, 5225–5232.
32. [32] Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, O'Leary JJ, Gottesman M, and Clynes M (2012). Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 7, e40717.
33. [33] Fletcher JI, Haber M, Henderson MJ, and Norris MD (2013). ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10, 147–156.
34. [34] Bouchet BP and Galmarini CM (2010). Cabazitaxel, a new taxane with favorable properties. Drugs Today (Barc) 46, 735–742.
35. [35] Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, Bellmunt J, Peters F, Le-Guennec S, and Cerbone L, et al (2013). Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology 85, 208–215.
36. [36] Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, and Fojo T (1996). Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52, 1855–1865.
37. [37] Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, and Berger W (2008). Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 11, 1–16.
38. [38] Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, and Marini L (2007). Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase II trial. Eur Urol 52, 134–141.
39. [39] Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, and Witjes JA (2011). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59, 1009–1018.
40. [40] Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, and Wiemer EA (2011). Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14, 22–34.
41. [41] Eroglu Z and Fruehauf JP (2013). A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemother Pharmacol 72, 263–267.
42. [42] Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, and Albanell J, et al (2007). Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 18, 1359–1362.